Medical Device Contract Manufacturing
Toxikon Corp. was founded as Cambridge Diagnostics in 1977 and reincorporated to its current namesake in 1982 by Dr. Laxman Desai, president and CEO. Prior to establishing the company, Dr. Desai managed oncology drug research programs at the Dana-Farber Cancer Institute in Boston. It is through his expertise that Toxikon became established in life sciences and has continued to advance innovations in the pharmaceutical, biotechnology, and medical device industries for more than 30 years. Toxikon’s safety services include toxicology (acute, subchronic, and chronic toxicity, reproductive toxicity, genetic toxicology, and carcinogenicity), pharmacokinetics, toxicokinetics, bioavailability, ADME, chemical characterization, impurities analysis and synthesis, bioanalytical, and microbiology/virology. Toxikon’s certifications and licenses allow it to meet extensive regulatory requirements for data acceptability.